Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to learn if Iparomlimab/Tuvonralimab combined with nab-paclitaxel and cisplatin as neoadjuvant treatment can treat locally advanced cervical cancer in adult female patients. It will also learn about the safety of this combination regimen. The main questions it aims to answer are: What is the pathological complete response (pCR) rate after neoadjuvant combination therapy? What are the objective response rate, progression-free survival, overall survival, biomarker changes and tumor immune microenvironment changes in participants receiving this regimen? There is no comparison group in this single-arm study. Participants will: * Receive neoadjuvant treatment with Iparomlimab/Tuvonralimab, albumin-bound paclitaxel and cisplatin * Undergo radical surgery after completion of neoadjuvant therapy * Receive scheduled imaging, blood and tissue biomarker tests * Be followed up regularly for survival and safety assessment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 18-70 lat
- •Potwierdzony rак szyjki macicy (typ płaskonabłonkowy, gruczolakowaty lub mieszany)
- •Rak w stopniu zaawansowania IB3 lub IIA2 według międzynarodowej klasyfikacji
- •Co najmniej jeden widoczny guz potwierdzony badaniem MRI
- •Dobry ogólny stan zdrowia (wynik 0 lub 1 w skali ECOG)
- •Wystarczająca liczba krwinek białych, płytek krwi i hemoglobiny
- •Prawidłowe funkcje nerek, wątroby i innych narządów
- •Kobieta w okresie reprodukcyjnym musi mieć negatywny test ciąży i zgodzić się na antykoncepcję
✗ Disqualifies
- •Obecne przerzuty do innych narządów (zaawansowana choroba)
- •Poprzednia chemioterapia, radioterapia lub inne leczenie onkologiczne
- •Ciąża lub karmienie piersią
- •Poważne problemy z funkcjonowaniem narządów wewnętrznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- October 15, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
The First Affiliated Hospital of Airforce Medical University
Xi'an, China
Trial contact
Shujuan Liu, MD
Xiaohui Lv, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.